Clinical Trial Update: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial sponsored by Bayer evaluating a new chemotherapy agent for non-small cell lung cancer has completed and reports safety and efficacy data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy Agent (study drug)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Non Small Cell Lung | Phase 2 | Status: COMPLETED